RESUMO
CONCLUSION: In platinumtaxane resistant epithelial ovarian cancer (EOC), we aimed to determine the effectiveness. PATIENTS AND METHODS: Between 2004 and 2013, patients afflicted with platinumtaxane resistant EOC and who were administered a 30-minute i.v. infusion of single-agent gemcitabine at a dose of 1,250 mg/m2 on the 1st, 8th and 15th days, every 28 days, were examined retrospectively. RESULTS: Twenty-six patients with platinumtaxane resistant EOC were included in the study. The overall survival (OS) was 48 months. The median survival after becoming platinumtaxane resistant was 16 months for the study population. Median time to progression (TTP) and median survival after becoming platinumtaxane resistant for patients who received second-line treatment were 3.3 months and 16 months, respectively; for patients who received third-line treatment with gemcitabine, these were 3.7 months and 19 months, respectively. Administration of gemcitabine as second- and third-line chemotherapy in platinumtaxane resistant EOC, provides similar TTP and OS outcomes (p = 0.4, p = 0.9) with a similar response and toxicity rate. CONCLUSIONS: Second- and third-line gemcitabine at a dose of 1,250 mg/m2 on days 1, 8 and 15 every 28 days as a 30-minute i.v. infusion in platinumtaxane resistant EOC is an effective treatment option with a tolerable and manageable toxicity.
